One of the most ambitious large-scale projects in Human Genetics has been launched today: Epitwin will capture the subtle epigenetic signatures that mark the differences between 5,000 twins on a scale and depth never before attempted, providing key therapeutic targets for the development of drug treatments.
The project is a collaboration between TwinsUK, a leading twin research group based at King's College London, and BGI, one of the world's largest genomic organisations headquartered in Shenzhen, China. Epigenetics is the most cutting edge emerging field in Genetics, which explores how the actions of genes can be temporarily modified by chemical reactions that may occur either at random or by lifestyle or diet. This effect may last several generations.
The plan is to look at the methylation patterns of 20 million sites (called CpG islands) in the DNA of each twin and compare them with the patterns in the co-twin. Rather than looking at similarities as in previous studies, the team will be looking for differences that explain why many identical twins don't develop the same diseases. Initially the team will focus on obesity, diabetes, allergies, heart disease, osteoporosis and longevity, but the method can be applied to every common trait or disease.
'Finding the crucial differences between twins will lead us to the key genes that are being turned on and off, and so to the cause of disease, with great potential to find key targets for drug treatments,' says Tim Spector, Director of TwinsUK and Professor of Genetic Epidemiology at King's College London, who is leading the project. 'The fact that twins are such a marvellous natural experiment, combined with the hundreds of disease details and traits on the twins that we have collected over 17 years, offer a unique study opportunity. So far this type of study has only been attempted on a handful of twins, so we want to scale it up one thousand fold.'
The Executive Director o
|Contact: Melanie Haberstroh|
King's College London